Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry. However, Viking's prominence and stock price soared thanks to excellent clinical progress. The biotech's shares are up by 154% since early January.

Can Viking Therapeutics perform nearly as well during the second half of the year? Is it already too late to buy the stock? Let's find out.

Viking's lead asset is VK2735, a potential weight loss therapy. Given how successful anti-obesity medicines like Wegovy (developed by Novo Nordisk) and Zepbound (marketed by Eli Lilly) have become, many companies are pouring funds into this area, trying to develop candidates that can compete with the leaders in the field.

Continue reading

Source Fool.com